New Insights Into Spinal Muscular Atrophy
Researchers from the University of Pennsylvania School of Medicine discovered that the effect of a protein deficiency, which is the basis of the neuromuscular disease spinal muscular atrophy (SMA), is not restricted to motor nerve cells, suggesting that SMA is a more general disorder.
High Quality Of Life In Spite Of Very Severe Disease
The authors showed that the quality of life of amyotrophic lateral sclerosis (ALS)patients does not depend on the severity of their physical restrictions. In contrast, it was found that patients who have to be given artificial respiration are more satisfied than patients for whom this is not necessary.
Steroid Use And Duchenne Muscular Dystrophy
The Muscular Dystrophy Campaign has received a number of calls from parents concerned about the possible side effects from steroid use and Duchenne muscular dystrophy.Professor Francesco Muntoni has advised parents and anyone concerned about possible side effects from steroid use and Duchenne muscular dystrophy to discuss their concerns directly with their consultant or their family doctor.
Amplifying The Fight Against ALS
Your ability to walk, swallow food and even breath depends on your brain's ability to talk to your muscles. Any interruption in this vital conversation is a major threat to your health. A recent discovery by Dr. Robert Brownstone, a neurosurgeon and researcher at Dalhousie University, may help keep the conversation going in people with amyotrophic lateral sclerosis (ALS).
Risk Of ALS Exposure In Gulf War Veterans Is Time Limited
A new study, led by researchers at the University of Cincinnati (UC), says that cases of Amyotrophic Lateral Sclerosis (ALS) among soldiers who served in the first Persian Gulf War were caused by certain events during their deployment to the war zone, meaning the exposure and illness is not as widespread as previously thought.
Risk Factors For Sudden Death For Adult Muscular Dystrophy Identified
The largest assessment of people with adult muscular dystrophy has identified risk factors that can lead to sudden death for individuals with the most common form of this disease. The results of the multicenter study, lead by the Indiana University School of Medicine, are reported in the June 19 issue of the New England Journal of Medicine.
PTC Therapeutics Announces Initiation Of Phase 2b Registration-Directed Clinical Trial Of PTC124 In Duchenne Becker Muscular Dystrophy
PTC Therapeutics, Inc. (PTC), today announced the initiation of an international pivotal trial of PTC124 in patients with Duchenne/Becker muscular dystrophy (DMD/BMD) due to a nonsense mutation. The primary objective of this registration-directed Phase 2b trial is to demonstrate the efficacy of PTC124 as measured by improvements in the walking ability of patients with this progressive genetic disease.
Long Term Physiotherapy Denied To Patients With Chronic Conditions, UK
On Wednesday 14 May the Muscular Dystrophy Campaign was joined by 135 supporters, clinicians and healthcare professionals, from around the country, at a Parliamentary reception to lobby Government to improve specialist services for people with neuromuscular conditions.
MDA Activities Focus Attention On National ALS Awareness Month
Throughout the month of May, the Muscular Dystrophy Association will highlight the 17th annual national ALS Awareness Month by hosting events in communities across the country and disseminating information about amyotrophic lateral sclerosis, or Lou Gehrig's disease.
Knopp Neurosciences Initiates Phase 2 Study Of KNS-760704 In Amyotrophic Lateral Sclerosis
Knopp Neurosciences Inc. ("Knopp") said it initiated the first Phase 2 study of KNS-760704 in patients with amyotrophic lateral sclerosis (ALS). The study is designed as a two-part, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of KNS-760704 oral tablets.